← Research library

Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.

Animal research · 2022

What was studied
Mouse models, cell assays including human osteoblasts, and observational human serum measurements
Main finding
The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.

Study data at a glance

Participants or experimental model
Mouse models, cell assays including human osteoblasts, and observational human serum measurements
Reported results
The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.
Study limitations and source details

Study limitations

  • Mouse treatment and cultured human cells do not demonstrate human treatment efficacy.
  • The human serum association cannot establish causation.
  • Full-length OGP and the active fragment must be distinguished in each experimental method.

Source details

Journal article

Original publication metadata and indexed abstract checked; full methods and tables not appraised.

Indexed abstract reviewed

Sources checked

Citation

Animal / experimentalEnglish abstract

B. Raphael-Mizrahi, M. Attar-Namdar, M. Chourasia, M. G. Cascio, Y. Gabet, et al.. Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2. eLife. 11:e65834

Study source ↗ · DOI 10.7554/eLife.65834 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards